

**side by
side**

**Count Name
result set**

DB=PGPB,USPT; PLUR=YES; OP=ADJ

L3 (gp39 of cd40L or cd40 adj ligand) and (tranpslant\$ or graft\$) same (ex adj
vivo or vitro)same (gp39 or cd40L or cd40 adj ligand)

19 L3

L2 L1 and (gp39 of cd40L or cd40 adj ligand)

15 L2

L1 noelle.in.

116 L1

END OF SEARCH HISTORY

09/835126

Search Results - Record(s) 1 through 10 of 15 returned.

1. 20020187135. 01 Oct 98. 12 Dec 02. METHODS FOR INDUCING ANTIGEN-SPECIFIC T CELL TOLERANCE. NOELLE, RANDOLPH J., et al. 424/93.71; 424/133.1 424/134.1 424/141.1 424/143.1 424/153.1 424/154.1 424/173.1 424/184.1 424/192.1 424/577 424/578 514/8 514/885 530/350 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75 A61K038/16 A01N063/00 A61K039/395 A61K039/40 A61K039/42 A61K039/00 A61K039/38 C07K001/00 C07K014/00 C07K017/00 C12P021/08 C07K016/00 A61K035/26 A61K035/28 A01N025/00.
2. 20020048579. 16 Apr 01. 25 Apr 02. Ex vivo treatment of allogeneic and xenogeneic donor T-cells containing compositions (bone marrow) using gp39 antagonists and use thereof. Noelle, Randolph J., et al. 424/144.1; 424/93.7 435/372 A61K039/395 C12N005/08.
3. 20020022020. 14 Sep 01. 21 Feb 02. Ex vivo treatment of allogeneic and xenogeneic donor T-cells containing compositions (bone marrow) using gp39 antagonists and use thereof. Noelle, Randolph J., et al. 424/93.71; 435/372 A61K045/00 C12N005/08.
4. 20010033840. 26 Jun 01. 25 Oct 01. Methods for inducing T cell tolerance to a tissue or organ graft. Noelle, Randolph J., et al. 424/144.1; A61K039/395.
5. 6472510. 14 Nov 94; 29 Oct 02. CD40 receptor ligands. Aruffo; Alejandro A., et al. 530/387.3; 530/350 530/866. C07K014/705 C07K014/71 C07K016/46.
6. 6376459. 31 Aug 93; 23 Apr 02. Inhibiting B cell activation with soluble CD40 or fusion proteins thereof. Aruffo; Alejandro A., et al. 514/2; 424/133.1 514/12 514/885 530/350 530/866 530/868. A61K038/02 A61K038/04.
7. 6375950. 05 Jan 99; 23 Apr 02. Methods for inducing T cell unresponsiveness to donor tissue or organ in a recipient with gp39 antagonists. Noelle; Randolph J., et al. 424/154.1; 424/130.1 424/133.1 424/134.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 424/184.1 424/192.1 424/577 424/93.7 424/93.71 514/2 514/8 514/885 530/350 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 A61K039/00 C07K016/28 C07K016/46 C07K014/705.
8. 6328964. 18 May 98; 11 Dec 01. Method to treat multiple sclerosis with GP39-specific antibodies. Noelle; Randolph J., et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/142.1 424/143.1 424/144.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 C07K016/28.
9. 6312692. 30 Apr 98; 06 Nov 01. Method of treating graft-versus-host disease with anti-GP39 antibodies and bone marrow cells. Noelle; Randolph J., et al. 424/154.1; 424/130.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 424/520 424/577 424/93.7 424/93.71 435/332 435/334 435/343 435/343.1 435/343.2 435/346 530/387.1 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 A61K035/28 C07K016/28.
10. 5942229. 07 Jun 95; 24 Aug 99. Method for prolonged suppression of humoral immune response to a thymus-dependent antigen therapeutic agent. Noelle; Randolph J., et al. 424/154.1;

Search Results - Record(s) 11 through 15 of 15 returned.

-
11. 5902585. 05 Aug 97; 11 May 99. Methods of inducing T cell unresponsiveness to donor tissue or organ in a recipient with GP39 antagonists. Noelle; Randolph J., et al. 424/144.1; 424/130.1 424/133.1 424/134.1 424/141.1 424/143.1 424/154.1 424/173.1 514/2 514/8 514/885 530/350 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 A61K035/26 C07K016/28 C07K014/435.
-
12. 5876718. 27 Mar 98; 02 Mar 99. Methods of inducing T cell non-responsiveness to transplanted tissues and of treating graft-versus-host-disease with anti-gp39 antibodies. Noelle; Randolph J., et al. 424/154.1; 424/130.1 424/133.1 424/134.1 424/141.1 424/143.1 424/193.1 435/326 435/332 435/334 435/343 435/343.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 C07K016/28 C12N005/12.
-
13. 5869049. 25 Apr 94; 09 Feb 99. Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists. Noelle; Randolph J., et al. 424/154.1; 424/130.1 424/134.1 424/143.1 424/144.1 424/173.1 424/233.1 514/12 514/2 514/8. A61K039/395 A61K037/02 A61K037/04.
-
14. 5747037. 07 Jun 95; 05 May 98. Anti-GP39 antibodies. Noelle; Randolph J., et al. 424/154.1; 424/130.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 435/326 435/332 435/334 435/343 435/343.1 435/343.2 435/346 435/70.21 530/387.1 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A01K039/395 C07K016/28 C12N005/12.
-
15. 5683693. 25 Apr 94; 04 Nov 97. Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40. Noelle; Randolph J., et al. 424/144.1; 424/130.1 424/133.1 424/134.1 424/141.1 424/143.1 424/154.1 424/173.1 514/2 514/8 514/885. A61K039/395 A61K038/17.
-

Term	Documents
GP39	313
GP39S	0
OF	169502
OFS	589
CD40L	1364
CD40LS	3
CD40	3354
CD40S	0
LIGAND	71190
LIGANDS	58356
(1 AND ((GP39 ADJ OF ADJ CD40L) OR (CD40 ADJ	15

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 10 of 19 returned.**

1. [20040052787](#). 06 Oct 03. 18 Mar 04. Methods for treating disorders of the female reproductive system. King, Anne Elizabeth, et al. 424/144.1; 530/388.22 A61K039/395 C07K016/28.
2. [20030219875](#). 12 Apr 01. 27 Nov 03. Albumin fusion proteins. Rosen, Craig A., et al. 435/69.7; 435/320.1 435/325 514/12 530/362 536/23.5 A61K038/38 C07H021/04 C12P021/04 C07K014/76.
3. [20030175269](#). 17 Jun 02. 18 Sep 03. Humanized antibodies to human gp39, compositions containing and therapeutic use thereof. Black, Amelia, et al. 424/141.1; 435/7.21 530/388.15 A61K039/395 C07K016/44 G01N033/567.
4. [20030170233](#). 17 Jun 02. 11 Sep 03. Treating Autoimmune Diseases with Humanized Anti-CD40L Antibody. Black, Amelia, et al. 424/141.1; 530/388.15 A61K039/395 C07K016/42.
5. [20030027744](#). 18 Apr 02. 06 Feb 03. Use of a CD40:CD154 binding interruptor to treat immunological complications of the eye. Dana, M. Reza, et al. 514/1; 514/2 A61K031/00 A61K038/00.
6. [20030012781](#). 06 Jun 01. 16 Jan 03. Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof. Darrell, Anderson, et al. 424/131.1; 424/93.21 A61K048/00 A61K039/395.
7. [20020187135](#). 01 Oct 98. 12 Dec 02. METHODS FOR INDUCING ANTIGEN-SPECIFIC T CELL TOLERANCE. NOELLE, RANDOLPH J., et al. 424/93.71; 424/133.1 424/134.1 424/141.1 424/143.1 424/153.1 424/154.1 424/173.1 424/184.1 424/192.1 424/577 424/578 514/8 514/885 530/350 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75 A61K038/16 A01N063/00 A61K039/395 A61K039/40 A61K039/42 A61K039/00 A61K039/38 C07K001/00 C07K014/00 C07K017/00 C12P021/08 C07K016/00 A61K035/26 A61K035/28 A01N025/00.
8. [20020048579](#). 16 Apr 01. 25 Apr 02. Ex vivo treatment of allogeneic and xenogeneic donor T-cells containing compositions (bone marrow) using gp39 antagonists and use thereof. Noelle, Randolph J., et al. 424/144.1; 424/93.7 435/372 A61K039/395 C12N005/08.
9. [20020022020](#). 14 Sep 01. 21 Feb 02. Ex vivo treatment of allogeneic and xenogeneic donor T-cells containing compositions (bone marrow) using gp39 antagonists and use thereof. Noelle, Randolph J., et al. 424/93.71; 435/372 A61K045/00 C12N005/08.
10. [6506383](#). 14 Jun 99; 14 Jan 03. Methods of suppressing immune responses to transplanted tissues and organs with gp39-specific antibodies. Black, Amelia, et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 C07K016/28.

[Generate Collection](#)[Print](#)

Term	Documents

Search Results - Record(s) 11 through 19 of 19 returned.

-
11. 6440418. 08 Sep 97; 27 Aug 02. Methods of treating autoimmune diseases with gp39-specific antibodies. Black; Amelia, et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 C07K016/28.
-
12. 6413514. 17 Dec 99; 02 Jul 02. Methods of using antibodies against human CD40. Aruffo; Alejandro A., et al. 424/144.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73. A61K039/395 C07K016/28.
-
13. 6312693. 10 Feb 99; 06 Nov 01. Antibodies against human CD40. Aruffo; Alejandro A., et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/173.1 435/252.2 435/320.1 435/326 435/328 435/332 435/334 435/343 435/343.1 435/455 435/471 435/69.6 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 536/23.1 536/23.5 5 36/23.53. A61K039/395 C07K016/28 C12N015/13.
-
14. 6312692. 30 Apr 98; 06 Nov 01. Method of treating graft-versus-host disease with anti-GP39 antibodies and bone marrow cells. Noelle; Randolph J., et al. 424/154.1; 424/130.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 424/520 424/577 424/93.7 424/93.71 435/332 435/334 435/343 435/343.1 435/343.2 435/346 530/387.1 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 A61K035/28 C07K016/28.
-
15. 6051228. 19 Feb 98; 18 Apr 00. Antibodies against human CD40. Aruffo; Alejandro A., et al. 424/144.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/153.1 424/173.1 435/252.3 435/320.1 435/452 530/387.1 530/387.3 530/388.2 530/388.22 530/388.7 530/388.73 536/23.53. A61K039/395 C07K016/28 C12N015/13 C12N001/21.
-
16. 6001358. 07 Nov 95; 14 Dec 99. Humanized antibodies to human gp39, compositions containing thereof. Black; Amelia, et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75 530/388.77 536/23.53. A61K039/395 C07K016/28.
-
17. 5876718. 27 Mar 98; 02 Mar 99. Methods of inducing T cell non-responsiveness to transplanted tissues and of treating graft-versus-host-disease with anti-gp39 antibodies. Noelle; Randolph J., et al. 424/154.1; 424/130.1 424/133.1 424/134.1 424/141.1 424/143.1 424/193.1 435/326 435/332 435/334 435/343 435/343.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 C07K016/28 C12N005/12.
-
18. 5869049. 25 Apr 94; 09 Feb 99. Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists. Noelle; Randolph J., et al. 424/154.1; 424/130.1 424/134.1 424/143.1 424/144.1 424/173.1 424/233.1 514/12 514/2 514/8. A61K039/395 A61K037/02 A61K037/04.
-
19. 5747037. 07 Jun 95; 05 May 98. Anti-GP39 antibodies. Noelle; Randolph J., et al. 424/154.1; 424/130.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 435/326 435/332 435/334 435/343 435/343.1 435/343.2 435/346 435/70.21 530/387.1 530/388.1 530/388.2 530/388.22 530/388.7